Company: CWAN
Filing Date: 2025-02-11
Form Type: S-4
Source: 0001193125-25-023759
Chunk: 45

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-02-11
Form: S-4
Chunk 45
---
 entitled to receive under the terms of the Merger Agreement. Enfusion Stockholders who wish to exercise the right to seek an appraisal of their shares must so advise Enfusion by submitting a written demand
for appraisal in the form described in this Proxy Statement/Prospectus prior to the vote to approve the Merger Agreement Proposal, and must otherwise follow the procedures prescribed by Section 262 of the DGCL. A person having a beneficial
interest in shares of Enfusion Common Stock or Enfusion Class B Common Stock held of record in the name of another person, such as a nominee or intermediary, must follow additional steps summarized in this Proxy Statement/Prospectus and in a
timely manner to perfect appraisal rights.

The text of Section 262 of the DGCL is attached as Annex E to this Proxy
Statement/Prospectus. You are encouraged to read these provisions carefully and in their entirety. Due to the complexity of the procedures for exercising appraisal rights, Enfusion Stockholders who are considering exercising such rights are
encouraged to seek the advice of legal counsel and their financial advisors. Failure to strictly comply with these provisions may result in the loss of appraisal rights.

No Solicitation of Other Offers by Enfusion(see page 130)

Under the terms of the Merger Agreement, Enfusion has agreed not to solicit, encourage or facilitate any competing acquisition proposals for
Enfusion, enter into discussions or negotiations with any third parties regarding any competing acquisition proposals for Enfusion or enter into any agreements with a third party regarding any competing acquisition proposals for Enfusion.

Notwithstanding the foregoing restrictions, if prior to Enfusion Stockholders adopting the Merger Agreement at the Special Meeting Enfusion
receives an unsolicited competing acquisition proposal that the Enfusion Board determines to be superior to the Transactions or reasonably be expected to lead to a proposal that is superior to the Transactions, Enfusion is permitted, subject to
certain conditions set forth in the Merger Agreement, to engage in discussions and negotiations with the party that sent the competing acquisition proposal (and its representatives, advisors and financing sources) and to furnish non-public information to that party (and its representatives, advisors and debt financing sources).

Under the terms of the Merger Agreement and subject to certain conditions set forth therein (including the payment of a $52,350,000
termination fee), Enfusion may terminate the Merger Agreement prior to Enfusion Stockholders adopting the Merger Agreement at the Special Meeting to accept a competing acquisition proposal that the Enfusion Board has determined to be